<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00005853</url>
  </required_header>
  <id_info>
    <org_study_id>1478.00</org_study_id>
    <secondary_id>FHCRC-1478.00</secondary_id>
    <secondary_id>NCI-G00-1793</secondary_id>
    <secondary_id>CDR0000067878</secondary_id>
    <nct_id>NCT00005853</nct_id>
  </id_info>
  <brief_title>Biological Therapy in Treating Patients With Myelodysplastic Syndrome</brief_title>
  <official_title>Therapy of Myelodysplastic Syndrome (MDS) With Antithymocyte Globulin (ATG) and TNFR:Fc</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fred Hutchinson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Fred Hutchinson Cancer Center</source>
  <brief_summary>
    <textblock>
      RATIONALE: Biological therapies use different ways to stimulate the immune system and stop&#xD;
      cancer cells from growing. Combining different types of biological therapies may kill more&#xD;
      cancer cells.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of biological therapy in treating patients&#xD;
      who have myelodysplastic syndrome.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the frequency of hematologic responses in patients with myelodysplastic&#xD;
           syndrome treated with anti-thymocyte globulin and tumor necrosis factor receptor IgG&#xD;
           chimera.&#xD;
&#xD;
        -  Correlate phenotypic, cytogenetic, and functional disease characteristics with treatment&#xD;
           responses in these patients.&#xD;
&#xD;
        -  Determine the safety of this treatment regimen in this patient population.&#xD;
&#xD;
      OUTLINE: Patients receive anti-thymocyte globulin IV over 8 hours daily for 4 days followed&#xD;
      by tumor necrosis factor receptor IgG chimera subcutaneously twice weekly for 16 weeks.&#xD;
&#xD;
      Patients are followed at 8, 16, and 20 weeks.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 15 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 1999</start_date>
  <completion_date type="Actual">August 2005</completion_date>
  <primary_completion_date type="Actual">August 2005</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Leukemia</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>anti-thymocyte globulin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>etanercept</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of myelodysplastic syndrome with no greater than 20% marrow blasts with:&#xD;
&#xD;
               -  Single or multilineage cytopenia (neutrophils less than 2,000/mm^3 and/or&#xD;
                  platelet count less than 100,000/mm^3 and/or reticulocyte count less than&#xD;
                  18,000/mm^3) OR&#xD;
&#xD;
               -  Transfusion requirement of at least 2 units packed red blood cells per month and&#xD;
                  one of the following:&#xD;
&#xD;
                    -  Suitable marrow donor unavailable&#xD;
&#xD;
                    -  Ineligible for a transplantation protocol&#xD;
&#xD;
                    -  Unwilling to proceed with transplantation&#xD;
&#xD;
          -  No chronic myelomonocytic leukemia&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  Any age&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No other severe disease that would preclude study&#xD;
&#xD;
          -  No active severe infection (e.g., pneumonia or septicemia) or severe infections within&#xD;
             the past 2 weeks&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 4 weeks since prior hematopoietic growth factors&#xD;
&#xD;
          -  No concurrent hematopoietic growth factors&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  At least 4 weeks since prior cytotoxic therapy&#xD;
&#xD;
          -  No concurrent cytotoxic therapy&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiation therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  At least 4 weeks since prior immunomodulatory therapy&#xD;
&#xD;
          -  No concurrent immunomodulatory therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>H. Joachim Deeg, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Fred Hutchinson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Research Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2010</verification_date>
  <study_first_submitted>June 2, 2000</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>March 31, 2010</last_update_submitted>
  <last_update_submitted_qc>March 31, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 2, 2010</last_update_posted>
  <keyword>refractory anemia</keyword>
  <keyword>refractory anemia with ringed sideroblasts</keyword>
  <keyword>refractory anemia with excess blasts</keyword>
  <keyword>refractory anemia with excess blasts in transformation</keyword>
  <keyword>de novo myelodysplastic syndromes</keyword>
  <keyword>previously treated myelodysplastic syndromes</keyword>
  <keyword>secondary myelodysplastic syndromes</keyword>
  <keyword>refractory cytopenia with multilineage dysplasia</keyword>
  <keyword>childhood myelodysplastic syndromes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Etanercept</mesh_term>
    <mesh_term>Antilymphocyte Serum</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

